Mesoblast (MESO) Rating Lowered to Hold at Zacks Investment Research

Mesoblast (NASDAQ:MESO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “

Several other research analysts have also recently weighed in on the stock. HC Wainwright set a $17.00 price objective on shares of Mesoblast and gave the company a “buy” rating in a report on Thursday, October 25th. Maxim Group restated a “buy” rating and set a $16.00 target price on shares of Mesoblast in a research report on Friday, October 12th. TheStreet upgraded shares of Mesoblast from a “d+” rating to a “c-” rating in a research report on Monday, October 1st. Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the company a “buy” rating in a research report on Monday, October 1st. Finally, ValuEngine upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Wednesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Mesoblast currently has a consensus rating of “Buy” and a consensus price target of $14.13.

MESO opened at $6.72 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.21 and a quick ratio of 4.21. Mesoblast has a twelve month low of $4.74 and a twelve month high of $8.78. The company has a market cap of $597.99 million, a PE ratio of -10.67 and a beta of 1.98.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings data on Wednesday, August 29th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Mesoblast had a negative net margin of 203.51% and a negative return on equity of 10.48%. The firm had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $2.51 million. As a group, research analysts predict that Mesoblast will post -0.97 EPS for the current fiscal year.

An institutional investor recently bought a new position in Mesoblast stock. Jane Street Group LLC purchased a new position in Mesoblast limited (NASDAQ:MESO) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,731 shares of the company’s stock, valued at approximately $102,000. Hedge funds and other institutional investors own 2.74% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Featured Story: Market Capitalization – What it Means for Investors

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply